Cargando…

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)

BACKGROUND: To compare the efficacy and safety of CAPIRI+bevacizumab (Bev) in comparison with FOLFIRI+Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC). METHODS: Patients were randomised to receive either FOLFIRI plus Bev 5 mg kg(−1) every 2 weeks (Arm-A) or CAPIRI pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Souglakos, J, Ziras, N, Kakolyris, S, Boukovinas, I, Kentepozidis, N, Makrantonakis, P, Xynogalos, S, Christophyllakis, Ch, Kouroussis, Ch, Vamvakas, L, Georgoulias, V, Polyzos, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273357/
https://www.ncbi.nlm.nih.gov/pubmed/22240792
http://dx.doi.org/10.1038/bjc.2011.594
_version_ 1782222924850135040
author Souglakos, J
Ziras, N
Kakolyris, S
Boukovinas, I
Kentepozidis, N
Makrantonakis, P
Xynogalos, S
Christophyllakis, Ch
Kouroussis, Ch
Vamvakas, L
Georgoulias, V
Polyzos, A
author_facet Souglakos, J
Ziras, N
Kakolyris, S
Boukovinas, I
Kentepozidis, N
Makrantonakis, P
Xynogalos, S
Christophyllakis, Ch
Kouroussis, Ch
Vamvakas, L
Georgoulias, V
Polyzos, A
author_sort Souglakos, J
collection PubMed
description BACKGROUND: To compare the efficacy and safety of CAPIRI+bevacizumab (Bev) in comparison with FOLFIRI+Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC). METHODS: Patients were randomised to receive either FOLFIRI plus Bev 5 mg kg(−1) every 2 weeks (Arm-A) or CAPIRI plus Bev 7.5 mg kg(−1) every 3 weeks (Arm-B). RESULTS: Three hundred thirty-three patients (Arm-A=167; Arm-B=166) were enrolled into the study. No difference was observed in median progression-free survival (PFS) (10.0 and 8.9 months; P=0.64), overall survival (25.7 and 27.5 months; P=0.55) or response rates (45.5 and 39.8.7% P=0.32) for FOLFIRI-Bev and CAPIRI-Bev, respectively. Patients treated with CAPIRI-Bev presented significantly higher incidence of diarrhoea (P=0.005), febrile neutropenia (P=0.003) and hand–foot skin reactions (P=0.02) compared with patients treated with FOLFIRI-Bev. Treatment delays (P=0.05), dose reduction (P<0.001) and treatment discontinuation owing to toxicity (P=0.01) occurred more frequently in the CAPIRI-Bev arm. CONCLUSION: The PFS of FOLFIRI-BEV is not superior to that observed with the CAPIRI-Bev regimen. CAPIRI-Bev has a less favourable toxicity profile, requiring dose reductions, in order to be considered as an option in first-line treatment of patients with mCRC.
format Online
Article
Text
id pubmed-3273357
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-32733572013-01-31 Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC) Souglakos, J Ziras, N Kakolyris, S Boukovinas, I Kentepozidis, N Makrantonakis, P Xynogalos, S Christophyllakis, Ch Kouroussis, Ch Vamvakas, L Georgoulias, V Polyzos, A Br J Cancer Clinical Studies BACKGROUND: To compare the efficacy and safety of CAPIRI+bevacizumab (Bev) in comparison with FOLFIRI+Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC). METHODS: Patients were randomised to receive either FOLFIRI plus Bev 5 mg kg(−1) every 2 weeks (Arm-A) or CAPIRI plus Bev 7.5 mg kg(−1) every 3 weeks (Arm-B). RESULTS: Three hundred thirty-three patients (Arm-A=167; Arm-B=166) were enrolled into the study. No difference was observed in median progression-free survival (PFS) (10.0 and 8.9 months; P=0.64), overall survival (25.7 and 27.5 months; P=0.55) or response rates (45.5 and 39.8.7% P=0.32) for FOLFIRI-Bev and CAPIRI-Bev, respectively. Patients treated with CAPIRI-Bev presented significantly higher incidence of diarrhoea (P=0.005), febrile neutropenia (P=0.003) and hand–foot skin reactions (P=0.02) compared with patients treated with FOLFIRI-Bev. Treatment delays (P=0.05), dose reduction (P<0.001) and treatment discontinuation owing to toxicity (P=0.01) occurred more frequently in the CAPIRI-Bev arm. CONCLUSION: The PFS of FOLFIRI-BEV is not superior to that observed with the CAPIRI-Bev regimen. CAPIRI-Bev has a less favourable toxicity profile, requiring dose reductions, in order to be considered as an option in first-line treatment of patients with mCRC. Nature Publishing Group 2012-01-31 2012-01-12 /pmc/articles/PMC3273357/ /pubmed/22240792 http://dx.doi.org/10.1038/bjc.2011.594 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Studies
Souglakos, J
Ziras, N
Kakolyris, S
Boukovinas, I
Kentepozidis, N
Makrantonakis, P
Xynogalos, S
Christophyllakis, Ch
Kouroussis, Ch
Vamvakas, L
Georgoulias, V
Polyzos, A
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
title Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
title_full Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
title_fullStr Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
title_full_unstemmed Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
title_short Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
title_sort randomised phase-ii trial of capiri (capecitabine, irinotecan) plus bevacizumab vs folfiri (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mcrc)
topic Clinical Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273357/
https://www.ncbi.nlm.nih.gov/pubmed/22240792
http://dx.doi.org/10.1038/bjc.2011.594
work_keys_str_mv AT souglakosj randomisedphaseiitrialofcapiricapecitabineirinotecanplusbevacizumabvsfolfirifolinicacid5fluorouracilirinotecanplusbevacizumabasfirstlinetreatmentofpatientswithunresectablemetastaticcolorectalcancermcrc
AT zirasn randomisedphaseiitrialofcapiricapecitabineirinotecanplusbevacizumabvsfolfirifolinicacid5fluorouracilirinotecanplusbevacizumabasfirstlinetreatmentofpatientswithunresectablemetastaticcolorectalcancermcrc
AT kakolyriss randomisedphaseiitrialofcapiricapecitabineirinotecanplusbevacizumabvsfolfirifolinicacid5fluorouracilirinotecanplusbevacizumabasfirstlinetreatmentofpatientswithunresectablemetastaticcolorectalcancermcrc
AT boukovinasi randomisedphaseiitrialofcapiricapecitabineirinotecanplusbevacizumabvsfolfirifolinicacid5fluorouracilirinotecanplusbevacizumabasfirstlinetreatmentofpatientswithunresectablemetastaticcolorectalcancermcrc
AT kentepozidisn randomisedphaseiitrialofcapiricapecitabineirinotecanplusbevacizumabvsfolfirifolinicacid5fluorouracilirinotecanplusbevacizumabasfirstlinetreatmentofpatientswithunresectablemetastaticcolorectalcancermcrc
AT makrantonakisp randomisedphaseiitrialofcapiricapecitabineirinotecanplusbevacizumabvsfolfirifolinicacid5fluorouracilirinotecanplusbevacizumabasfirstlinetreatmentofpatientswithunresectablemetastaticcolorectalcancermcrc
AT xynogaloss randomisedphaseiitrialofcapiricapecitabineirinotecanplusbevacizumabvsfolfirifolinicacid5fluorouracilirinotecanplusbevacizumabasfirstlinetreatmentofpatientswithunresectablemetastaticcolorectalcancermcrc
AT christophyllakisch randomisedphaseiitrialofcapiricapecitabineirinotecanplusbevacizumabvsfolfirifolinicacid5fluorouracilirinotecanplusbevacizumabasfirstlinetreatmentofpatientswithunresectablemetastaticcolorectalcancermcrc
AT kouroussisch randomisedphaseiitrialofcapiricapecitabineirinotecanplusbevacizumabvsfolfirifolinicacid5fluorouracilirinotecanplusbevacizumabasfirstlinetreatmentofpatientswithunresectablemetastaticcolorectalcancermcrc
AT vamvakasl randomisedphaseiitrialofcapiricapecitabineirinotecanplusbevacizumabvsfolfirifolinicacid5fluorouracilirinotecanplusbevacizumabasfirstlinetreatmentofpatientswithunresectablemetastaticcolorectalcancermcrc
AT georgouliasv randomisedphaseiitrialofcapiricapecitabineirinotecanplusbevacizumabvsfolfirifolinicacid5fluorouracilirinotecanplusbevacizumabasfirstlinetreatmentofpatientswithunresectablemetastaticcolorectalcancermcrc
AT polyzosa randomisedphaseiitrialofcapiricapecitabineirinotecanplusbevacizumabvsfolfirifolinicacid5fluorouracilirinotecanplusbevacizumabasfirstlinetreatmentofpatientswithunresectablemetastaticcolorectalcancermcrc